Literature DB >> 15473409

Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis.

Nithima Chaowalit1, Patricia A Pellikka, Paul A Decker, Marie-Christine Aubry, Michael J Krowka, Jay H Ryu, Robert Vassallo.   

Abstract

OBJECTIVE: To determine the echocardiographic characteristics and impact on survival of pulmonary hypertension (PH) and correlations between echocardiographic and clinical variables in patients with pulmonary Langerhans cell histiocytosis (PLCH). PATIENTS AND METHODS: Of 123 adults seen at our institution between January 1976 and December 2002 with histologically proven PLCH, 17 underwent echocardiographic evaluation. Correlations were performed between echocardiographic measures of PH and clinical variables. Cumulative survival probabilities for patients with PH were estimated using the Kaplan-Meier method and were compared to a historical cohort of patients with PLCH using time-dependent proportional hazard regression.
RESULTS: Of the 17 patients, PH (estimated pulmonary artery systolic pressure [PASP] at rest, > 35 mm Hg) was present in 15. Thirteen patients (6 men; median PASP, 67 mm Hg; range, 41.2-90.6 mm Hg) had no other known causes of PH. All patients were smokers. Nine patients had a PASP of more than 50 mm Hg. An inverse correlation was found between the forced vital capacity and PASP (r = -0.61; P = .03); no correlation was found between PASP and other pulmonary function parameters. Seven patients with a PASP greater than 65 mm Hg had an enlarged right ventricle with impaired systolic function. The development of PH in patients with PLCH was associated with increased mortality (hazard ratio, 22.8; 95% confidence interval, 7.6 to > 68.9; P < .001).
CONCLUSION: Severe PH occurs in PLCH, correlates with the forced vital capacity, and has a significant impact on survival. Clinicians should consider echocardiographic screening for PH in all dyspneic patients with PLCH.

Entities:  

Mesh:

Year:  2004        PMID: 15473409     DOI: 10.4065/79.10.1269

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  10 in total

1.  [Histopathological aspects of pulmonary hypertension].

Authors:  D Jonigk; M M Hoeper; H Kreipe; F Länger
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

Review 2.  Rare lung diseases III: pulmonary Langerhans' cell histiocytosis.

Authors:  Stephen C Juvet; David Hwang; Gregory P Downey
Journal:  Can Respir J       Date:  2010 May-Jun       Impact factor: 2.409

Review 3.  Smoking-related interstitial lung disease.

Authors:  Lars Hagmeyer; Winfried Randerath
Journal:  Dtsch Arztebl Int       Date:  2015-01-23       Impact factor: 5.594

Review 4.  Cigarette smoking and diffuse lung disease.

Authors:  Rajesh R Patel; Jay H Ryu; Robert Vassallo
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Pulmonary langerhans cell histiocytosis.

Authors:  Harpreet S Suri; Eunhee S Yi; Gregorz S Nowakowski; Robert Vassallo
Journal:  Orphanet J Rare Dis       Date:  2012-03-19       Impact factor: 4.123

6.  Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy.

Authors:  Adam May; Garvan Kane; Eunhee Yi; Robert Frantz; Robert Vassallo
Journal:  Respir Med Case Rep       Date:  2014-11-22

Review 7.  Pulmonary langerhans cell histiocytosis: case series and literature review.

Authors:  Ping Wei; Hai-Wen Lu; Sen Jiang; Li-Chao Fan; Hui-Ping Li; Jin-Fu Xu
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

Review 8.  Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension.

Authors:  Mazen Al-Qadi; Barbara LeVarge; H James Ford
Journal:  Front Med (Lausanne)       Date:  2021-03-25

9.  Long-term improvement during tadalafil therapy in a patient with pulmonary hypertension secondary to pulmonary Langerhans cell histiocytosis.

Authors:  Kenji Nemoto; Shuji Oh-Ishi; Toshihide Inui; Mariko Nakazawa; Kentaro Hyodo; Masayuki Nakajima; Jun Kanazawa; Yukiko Miura; Takio Takaku; Yuko Minami; Kenji Hayashihara; Takefumi Saito; Yoshinori Kawabata
Journal:  Respir Med Case Rep       Date:  2016-04-25

10.  Pulmonary Langerhans Cell Histiocytosis Associated with Bronchogenic Carcinoma.

Authors:  Muhammad F Khaliq; Muhammad M Noorani; Syed Maaz Tariq; Ashish Koirala; Hesham Mohamed
Journal:  Cureus       Date:  2020-01-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.